BioNTech’s Oncology Ambition Faces a Trio of Tests: Clinical Data, Founder Departure, and Deep Cost-Cutting
BioNTech is entering a period where scientific validation, financial discipline, and leadership transition all converge. The stock closed Tuesday at...












